LeonaBio, Inc. (LONA) stock
LONANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.65−0.11 (-3.99%)
Close on Nov 18, 2026Market cap $24.97MP/E –Yield –
LeonaBio r&d expenses
Research and development expenses are spending on new products and technology.
LeonaBio's R&D Expenses for the twelve months ending Jun 30, 2026 was $33.50M, down 5.0% year over year. For fiscal 2025 it was $17.50M, down 75.2% from the year before. The highest annual figure on record is $93.79M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.50M | -75.2% |
| FY2024 | Dec 31, 2024 | $70.68M | -24.6% |
| FY2023 | Dec 31, 2023 | $93.79M | +52.6% |
| FY2022 | Dec 31, 2022 | $61.46M | +43.6% |
| FY2021 | Dec 31, 2021 | $42.79M | +222.1% |
| FY2020 | Dec 31, 2020 | $13.29M | +250.3% |
| FY2019 | Dec 31, 2019 | $3.79M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $12.70M | +247.0% |
| Q1 FY2026 | Mar 31, 2026 | $11.26M | +161.8% |
| Q4 FY2025 | Dec 31, 2025 | $6.71M | -28.4% |
| Q3 FY2025 | Sep 30, 2025 | $2.83M | -84.2% |
| Q2 FY2025 | Jun 30, 2025 | $3.66M | -83.5% |
| Q1 FY2025 | Mar 31, 2025 | $4.30M | -79.7% |
| Q4 FY2024 | Dec 31, 2024 | $9.37M | -60.4% |
| Q3 FY2024 | Sep 30, 2024 | $17.92M | -34.1% |
| Q2 FY2024 | Jun 30, 2024 | $22.15M | +2.5% |
| Q1 FY2024 | Mar 31, 2024 | $21.24M | -0.3% |
| Q4 FY2023 | Dec 31, 2023 | $23.68M | +55.4% |
| Q3 FY2023 | Sep 30, 2023 | $27.20M | +60.3% |
| Q2 FY2023 | Jun 30, 2023 | $21.62M | +46.0% |
| Q1 FY2023 | Mar 31, 2023 | $21.29M | +47.3% |
| Q4 FY2022 | Dec 31, 2022 | $15.24M | +20.7% |
| Q3 FY2022 | Sep 30, 2022 | $16.97M | +58.4% |
| Q2 FY2022 | Jun 30, 2022 | $14.80M | +23.1% |
| Q1 FY2022 | Mar 31, 2022 | $14.46M | +94.2% |
| Q4 FY2021 | Dec 31, 2021 | $12.62M | +143.3% |
| Q3 FY2021 | Sep 30, 2021 | $10.71M | +83.7% |
| Q2 FY2021 | Jun 30, 2021 | $12.02M | +617.0% |
| Q1 FY2021 | Mar 31, 2021 | $7.45M | +1157.6% |
| Q4 FY2020 | Dec 31, 2020 | $5.19M | +688.3% |
| Q3 FY2020 | Sep 30, 2020 | $5.83M | +468.2% |
| Q2 FY2020 | Jun 30, 2020 | $1.68M | – |
| Q1 FY2020 | Mar 31, 2020 | $592.00K | – |
| Q4 FY2019 | Dec 31, 2019 | $658.00K | – |
| Q3 FY2019 | Sep 30, 2019 | $1.03M | – |
See a number that looks wrong?